Karyopharm Therapeutics Inc (KPTI)

$1.17

-0.11

(-8.59%)▲

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Karyopharm Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 38.69M → 33.74M (in $), with an average decrease of 4.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -32.63M → -41.83M (in $), with an average decrease of 13.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 117.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 323.8%

Performance

  • $1.14
    $1.31
    $1.17
    downward going graph

    2.56%

    Downside

    Day's Volatility :12.64%

    Upside

    10.34%

    downward going graph
  • $0.62
    $4.11
    $1.17
    downward going graph

    47.23%

    Downside

    52 Weeks Volatility :84.98%

    Upside

    71.53%

    downward going graph

Returns

PeriodKaryopharm Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
67.1%
-0.7%
0.0%
6 Months
20.75%
7.7%
0.0%
1 Year
-69.08%
3.3%
-1.7%
3 Years
-86.13%
13.9%
-20.7%

Highlights

Market Capitalization
147.3M
Book Value
- $1.18
Earnings Per Share (EPS)
-1.25
PEG Ratio
-0.15
Wall Street Target Price
5.57
Profit Margin
-97.99%
Operating Margin TTM
-112.03%
Return On Assets TTM
-27.05%
Return On Equity TTM
-891.05%
Revenue TTM
146.0M
Revenue Per Share TTM
1.28
Quarterly Revenue Growth YOY
0.5%
Gross Profit TTM
151.9M
EBITDA
-129.0M
Diluted Eps TTM
-1.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.23
EPS Estimate Next Year
-1.01
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Karyopharm Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 376.07%

Current $1.17
Target $5.57

Company Financials

FY18Y/Y Change
Revenue
30.3M
↑ 1790.09%
Net Income
-178.4M
↑ 38.32%
Net Profit Margin
-588.1%
↑ 7448.29%
FY19Y/Y Change
Revenue
40.9M
↑ 34.8%
Net Income
-199.6M
↑ 11.87%
Net Profit Margin
-488.08%
↑ 100.02%
FY20Y/Y Change
Revenue
108.1M
↑ 164.31%
Net Income
-196.3M
↓ 1.66%
Net Profit Margin
-181.59%
↑ 306.49%
FY21Y/Y Change
Revenue
209.8M
↑ 94.12%
Net Income
-124.1M
↓ 36.78%
Net Profit Margin
-59.14%
↑ 122.45%
FY22Y/Y Change
Revenue
157.1M
↓ 25.14%
Net Income
-165.3M
↑ 33.2%
Net Profit Margin
-105.23%
↓ 46.09%
FY23Y/Y Change
Revenue
146.0M
↓ 7.03%
Net Income
-143.1M
↓ 13.43%
Net Profit Margin
-97.99%
↑ 7.24%
Q3 FY22Q/Q Change
Revenue
36.1M
↓ 8.91%
Net Income
-36.3M
↓ 25.96%
Net Profit Margin
-100.5%
↑ 23.15%
Q4 FY22Q/Q Change
Revenue
33.6M
↓ 7.1%
Net Income
-38.5M
↑ 6.01%
Net Profit Margin
-114.67%
↓ 14.17%
Q1 FY23Q/Q Change
Revenue
38.7M
↑ 15.24%
Net Income
-34.1M
↓ 11.37%
Net Profit Margin
-88.19%
↑ 26.48%
Q2 FY23Q/Q Change
Revenue
37.6M
↓ 2.89%
Net Income
-32.6M
↓ 4.38%
Net Profit Margin
-86.83%
↑ 1.36%
Q3 FY23Q/Q Change
Revenue
36.0M
↓ 4.18%
Net Income
-34.5M
↑ 5.75%
Net Profit Margin
-95.83%
↓ 9.0%
Q4 FY23Q/Q Change
Revenue
33.7M
↓ 6.28%
Net Income
-41.8M
↑ 21.25%
Net Profit Margin
-123.97%
↓ 28.14%
FY18Y/Y Change
Total Assets
341.2M
↑ 89.24%
Total Liabilities
158.0M
↑ 210.88%
FY19Y/Y Change
Total Assets
295.0M
↓ 13.55%
Total Liabilities
245.2M
↑ 55.16%
FY20Y/Y Change
Total Assets
313.1M
↑ 6.13%
Total Liabilities
262.5M
↑ 7.06%
FY21Y/Y Change
Total Assets
305.3M
↓ 2.47%
Total Liabilities
385.0M
↑ 46.66%
FY22Y/Y Change
Total Assets
358.2M
↑ 17.32%
Total Liabilities
374.8M
↓ 2.64%
FY23Y/Y Change
Total Assets
240.4M
↓ 32.87%
Total Liabilities
376.6M
↑ 0.48%
Q3 FY22Q/Q Change
Total Assets
231.2M
↓ 9.84%
Total Liabilities
371.5M
↓ 0.35%
Q4 FY22Q/Q Change
Total Assets
358.2M
↑ 54.89%
Total Liabilities
374.8M
↑ 0.89%
Q1 FY23Q/Q Change
Total Assets
325.8M
↓ 9.04%
Total Liabilities
371.0M
↓ 1.03%
Q2 FY23Q/Q Change
Total Assets
297.8M
↓ 8.59%
Total Liabilities
369.1M
↓ 0.51%
Q3 FY23Q/Q Change
Total Assets
270.0M
↓ 9.36%
Total Liabilities
370.4M
↑ 0.35%
Q4 FY23Q/Q Change
Total Assets
240.4M
↓ 10.94%
Total Liabilities
376.6M
↑ 1.7%
FY18Y/Y Change
Operating Cash Flow
-159.1M
↑ 115.85%
Investing Cash Flow
-107.7M
↓ 729.32%
Financing Cash Flow
316.1M
↑ 317.34%
FY19Y/Y Change
Operating Cash Flow
-190.8M
↑ 19.93%
Investing Cash Flow
78.5M
↓ 172.87%
Financing Cash Flow
124.3M
↓ 60.68%
FY20Y/Y Change
Operating Cash Flow
-160.2M
↓ 16.03%
Investing Cash Flow
-53.7M
↓ 168.43%
Financing Cash Flow
172.1M
↑ 38.44%
FY21Y/Y Change
Operating Cash Flow
-107.1M
↓ 33.15%
Investing Cash Flow
141.8M
↓ 364.21%
Financing Cash Flow
73.6M
↓ 57.2%
FY22Y/Y Change
Operating Cash Flow
-149.6M
↑ 39.62%
Investing Cash Flow
-104.3M
↓ 173.5%
Financing Cash Flow
193.7M
↑ 163.06%
Q3 FY22Q/Q Change
Operating Cash Flow
-28.4M
↓ 19.27%
Investing Cash Flow
11.7M
↓ 131.9%
Financing Cash Flow
5.8M
↑ 341.66%
Q4 FY22Q/Q Change
Operating Cash Flow
-26.8M
↓ 5.38%
Investing Cash Flow
-65.3M
↓ 659.39%
Financing Cash Flow
155.8M
↑ 2587.41%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.9M
↓ 29.55%
Investing Cash Flow
-32.4M
↓ 50.4%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Karyopharm Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
-6.57%
20.75%
-69.08%
-86.13%
-73.61%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
NA
NA
-0.15
-1.23
-8.91
-0.27
NA
-1.18
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.3
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Buy
$147.3M
-73.61%
NA
-97.99%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$547.4B
410.4%
46.3
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    8.75%

  • Vanguard Group Inc

    7.57%

  • Avidity Partners Management LP

    7.21%

  • Palo Alto Investors, LLC

    4.43%

  • Citadel Advisors Llc

    2.70%

  • Goldman Sachs Group Inc

    2.25%

Corporate Announcements

  • Karyopharm Therapeutics Inc Earnings

    Karyopharm Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Organization
Karyopharm Therapeutics Inc
Employees
325
CEO
Mr. Richard A. Paulson M.B.A.
Industry
Health Technology

Discover More

FAQs